7AL0
Research 7AL0 on Bullrun: market cap EUR 62.81K. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- Ticker7AL0
- ExchangeF
- CountrySweden
- SectorHealthcare
- IndustryBiotechnology
- CurrencyEUR
- Market capEUR 62.81K
- Financial periodQ1 2026
- RevenueSEK 0
- Net incomeSEK 1.44M
- Free cash flow-SEK 38.65M
Valuation Snapshot
latest market cap is EUR 62.81K.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | n/a | n/a | n/a | n/a | -1.4 | SEK 62.20M | SEK 43.15M | SEK 6.86M |
| FY2024 | SEK 57.77M | -SEK 233.89M | -SEK 212.43M | n/a | -0.32 | SEK 64.31M | SEK 180.81M | -SEK 130.59M |
| FY2023 | SEK 58.11M | -SEK 248.59M | -SEK 191.74M | n/a | -0.55 | SEK 66.12M | n/a | SEK 11.86M |
| FY2022 | SEK 35.70M | -SEK 193.40M | -SEK 173.05M | n/a | -0.88 | SEK 97.31M | n/a | SEK 89.05M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-24 | EUR 62.81K | n/a | n/a | 0 |
Dividend history
Latest trailing dividend snapshot: annual dividend/share 0 EUR.
About 7AL0
Alligator Bioscience AB (publ), a research-based biotechnology company, develops antibody-based pharmaceuticals for cancer treatment in Belgium. The company develops Mitazalimab, a stimulatory antibody that targets CD40, which is in phase 3 clinical trial for the treatment of solid metastatic tumors, including pancreatic cancer;
Related stock research
Other Healthcare stocks
Frequently asked questions
What is 7AL0's market cap?
7AL0's market capitalization is EUR 62.81K.
What does 7AL0 do?
Alligator Bioscience AB (publ), a research-based biotechnology company, develops antibody-based pharmaceuticals for cancer treatment in Belgium. The company develops Mitazalimab, a stimulatory antibody that targets CD40, which is in phase 3 clinical trial for the treatment of solid metastatic tumors, including pancreatic cancer; and ATOR-4066, tumor-directed bispecific antibody, developed using Neo-X-Prime technology platform for immunotherapy, which is in preclinical stage for the treatment of solid metastatic tumors.